Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392547 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
A Phase 3 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT01392547: Completed Phase 3 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S.
NCT01392547 is a Phase 3 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors that has completed, run by Novo Nordisk A/S. The registered enrollment target is 72 participants, below the 130-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01392547, a Phase 3 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.
Conditions Studied
Interventions
- DRUG vatreptacog alfa (activated)
- DRUG eptacog alfa (activated)
Study Locations (20)
Other
- - Linz
- - Zagreb
- - Athens
- - Budapest
- - Milan
California
- Novo Nordisk Clinical Trial Call Center - Los Angeles
- Novo Nordisk Clinical Trial Call Center - Los Angeles
- Novo Nordisk Clinical Trial Call Center - Orange
Georgia
- Novo Nordisk Clinical Trial Call Center - Atlanta
- Novo Nordisk Clinical Trial Call Center - Augusta
Arizona
- Novo Nordisk Clinical Trial Call Center - Tucson
Colorado
- Novo Nordisk Clinical Trial Call Center - Aurora
Florida
- Novo Nordisk Clinical Trial Call Center - Tampa
Iowa
- Novo Nordisk Clinical Trial Call Center - Iowa City
Massachusetts
- Novo Nordisk Clinical Trial Call Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
What the finished NCT01392547 record still lists
NCT01392547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 130-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Congenital Bleeding Disorder appearing as the primary indexed condition, and to 2 interventions - of which vatreptacog alfa (activated) is the first listed.
NCT01392547 names 20 study sites across 13 states, led by Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01392547 about?
NCT01392547 is a clinical study titled "Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors". This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.
What is the current status of trial NCT01392547?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2011-07. Estimated completion is 2012-08.
What conditions does trial NCT01392547 study?
This clinical trial studies the following conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors.
What interventions are being tested in trial NCT01392547?
The interventions under investigation include: vatreptacog alfa (activated) (DRUG), eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT01392547?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01392547 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Bleeding Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01392547's enrollment target sits among peer trials
72 4th of 8 higher than 5 of 8 other Congenital Bleeding Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Bleeding Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
COMPLETED · Phase 3
-
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
COMPLETED · Phase 3
-
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
COMPLETED · Phase 3
-
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia